E-6201
As of the edition of 20 October 2026, E-6201 is a small molecule: stopped in 2025; acts on MAP2K1 and MAP3K1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 6, 3 stopped early
- Disease areas
- Cancer; Nervous system; Skin and connective tissue; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
4 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product4 company-target rows are on route A because of E-6201.
See the 4 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 1 | 0 | 2 |
| Phase 2 | 3 | 2 | 0 | 1 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eisai | Lead sponsor of trials | 2007 to now |
| Spirita Oncology | Lead sponsor of trials | 2015 to now |